Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
63 hedge funds and large institutions have $41.2M invested in Soleno Therapeutics in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
6% less funds holding
Funds holding: 67 → 63 (-4)
15.13% less ownership
Funds ownership: 56.12% → 40.99% (-15%)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
44% less call options, than puts
Call options by funds: $179K | Put options by funds: $320K
52% less capital invested
Capital invested by funds: $86.2M → $41.2M (-$45.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$995K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$374K |
| 3 |
OC
Oppenheimer & Co
New York
|
+$331K |
| 4 |
State Street
Boston,
Massachusetts
|
+$269K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$11.1M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$3.72M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.31M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.99M |
| 5 |
AIC
AWM Investment Company
New York
|
-$2.25M |
SLNO Hedge Fund Activity: Q1 2021 in Review
63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2021, worth a combined $41.2M — down 52% from $86.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SLNO and 8 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 20 added.
The largest buyer was Vanguard Group, adding an estimated $995K. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $11.1M sold.
- 63 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2021, down from 67 in Q4 2020.
- Funds reported $41.2M of Soleno Therapeutics stock for Q1 2021, down 52% quarter-over-quarter.
- 8 funds opened new Soleno Therapeutics positions in Q1 2021 and 12 closed out, a net change of -4 holders.
- The largest Soleno Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $995K added.
- The largest Soleno Therapeutics seller in Q1 2021 was Suvretta Capital Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2021.